Results 161 to 170 of about 39,064 (303)

Trading between perceived risks and benefits related to biosimilar biological treatment in Crohn’s disease; discrete choice experiment among gastroenterologists [PDF]

open access: yes, 2015
Objective: The objective of the study is to explore preferences of gastroenterologists for biosimilar drugs in Crohn’s Disease and reveal trade-offs between the perceived risks and benefits related to biosimilar drugs.
Baji, Petra   +7 more
core  

Growth hormone receptor antagonists, GHA2 and GHA3, with dual activity against the human and mouse receptor

open access: yesProtein Science, Volume 34, Issue 8, August 2025.
Abstract Aberrant human growth hormone (GH) expression has been increasingly linked to poor outcomes in certain cancers and reduced health span. GH receptor (GHR) signal transduction activates signaling pathways that promote cell proliferation and survival, contributing to tumor progression.
Yue Wang   +5 more
wiley   +1 more source

Photocatalytic Diselenide Contraction as a Tool for Site‐Selective Isosteric Ubiquitylation

open access: yesJournal of Peptide Science, Volume 31, Issue 8, August 2025.
Chemoselective photocatalytic diselenide contraction (PDC) enables site‐selective biomimetic ubiquitylation of substrate peptides. The resulting selenalysine linkage undergoes efficient cleavage by deubiquitylating enzymes. ABSTRACT Ubiquitylation is a highly conserved post‐translational modification (PTM) in eukaryotes, which serves as a critical ...
Herwig Weissinger   +4 more
wiley   +1 more source

Biosimilars are not (bio)generics [PDF]

open access: diamond, 2010
K. L. Lynch   +2 more
openalex   +1 more source

The Optimal Timing and Duration of Daily G‐CSF for the Primary Prevention of Febrile Neutropenia in Breast Cancer Patients Undergoing Adjuvant TAC Chemotherapy

open access: yesAsia-Pacific Journal of Clinical Oncology, Volume 21, Issue 4, Page 383-391, August 2025.
The study aimed to determine the optimal timing and duration of filgrastim administration for the primary prevention of febrile neutropenia (FN) in breast cancer patients undergoing adjuvant TAC chemotherapy. Our findings suggest that initiating daily filgrastim from Day 2 and continuing for 7 days optimizes toxicity reduction.
Zisun Kim   +7 more
wiley   +1 more source

Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies [PDF]

open access: gold, 2010
Hongwei Xie   +8 more
openalex   +1 more source

Sex‐Related Differences in Efficacy and Safety Outcomes in Axial Spondyloarthritis Randomized Clinical Trials: A Systematic Literature Review and Meta‐Analysis

open access: yesArthritis Care &Research, Volume 77, Issue 7, Page 813-826, July 2025.
Objective We aimed to assess differences in baseline characteristics, efficacy, and safety of advanced therapies between male and female patients with axial spondyloarthritis (axSpA) in randomized controlled trials (RCTs). Methods We conducted a systematic literature search for RCTs assessing the efficacy of advanced therapies in patients with axSpA ...
Angel Gao   +5 more
wiley   +1 more source

PSY15 Striving for Affordable Treatments Within the Greek Environment: Do Epoetin Biosimilars Help? [PDF]

open access: bronze, 2011
Chara Kani   +5 more
openalex   +1 more source

Appraising the visibility, relevance and impacts of clinical pharmacology

open access: yesBritish Journal of Clinical Pharmacology, Volume 91, Issue 7, Page 1884-1898, July 2025.
Aims Clinical pharmacology (CP) used to be a strong medical and scientific field, but during the last three decades it seems to have lost some of its appeal. We reviewed the visibility, relevance and impact of CP and clinical pharmacologists across the globe and suggest ways to strengthen the discipline to address future pharmacotherapeutic challenges.
Serge Cremers   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy